Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for rare, severe psoriasis

NCT ID NCT06295692

Disease control Sponsor: Janssen Pharmaceutical K.K. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 01, 2026 · Updated 5 times

Summary

This phase 3 trial tests an oral drug called JNJ-77242113 in 19 people with two rare and severe forms of psoriasis: generalized pustular psoriasis and erythrodermic psoriasis. The study measures how many participants see improvement after 16 weeks of treatment. It is an open-label study, meaning everyone knows they are getting the drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
JNJ-77242113 (an oral tablet)
What this could lead to
If successful, this could provide a new oral treatment option for people with severe, rare forms of psoriasis that are hard to manage.
What could go wrong
This is a small, open-label study with only 19 participants, so results may not apply to everyone. The drug may not work as well in larger groups or have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

19 people

The number who actually took part.

Started

Feb 2024

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The study participant has a diagnosis of generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP) at screening. For GPP, a diagnosis must be classified based on the criteria for diagnosis of GPP by the Japanese Dermatological Association (JDA); for EP, has a history of plaque-type psoriasis. In addition, has an involved body surface area (BSA) of lesion greater than or equal to (\>=) 80 percent (%) at baseline * Candidate for phototherapy or systemic treatment for psoriasis (either naive or history of previous treatment) * A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta-human chorionic gonadotropin \[beta-hCG\]) at screening and have a negative urine pregnancy test at Week 0 prior to administration of study intervention * A male participant must agree not to plan to father a child while enrolled in this study or within 90 days after the last dose of study intervention * A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after receiving the last dose of study intervention Exclusion Criteria: * The study participant has a total score of JDA severity index for GPP \>=14 at baseline if participants have a diagnosis of GPP * The study participant has a differential diagnosis of the erythroderma (for example, erythroderma caused by lymphoma or drug eruption) other than EP * The study participant has a history of or current diagnosis or signs or symptoms of severe, progressive, or uncontrolled liver, renal; cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances * The study participant has a history of amyloidosis * Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients * The study participant who doesn't meet the criteria of prior/current concomitant therapy and/or history/conditions of infections

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Erythrodermic psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

generalized pustular psoriasis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Erythrodermic psoriasis Generalized pustular psoriasis

Contacts and locations

Locations

  • Dokkyo Medical University Hospital

    Shimotsuga Gun, 321 0293, Japan

  • Fujita Health University Hospital

    Toyoake, 470-1192, Japan

  • Hospital of the University of Occupational and Environmental Health

    Kitakyushu-shi, 807-8556, Japan

  • Ichinomiya Municipal Hospital

    Ichinomiya, 491-8558, Japan

  • JR Sapporo Hospital

    Hokkaido, 060-0033, Japan

  • Kumamoto University Hospital

    Kumamoto, 860-8556, Japan

  • Mie University Hospital

    Tsu, 514 8507, Japan

  • Nagoya City University Hospital

    Nagoya, 467 8602, Japan

  • Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital

    Osaka, 550 0006, Japan

  • Teikyo University Hospital

    Itabashi Ku, 173 8606, Japan

  • Tohoku University Hospital

    Sendai, 980 8574, Japan

  • Tokyo Medical University Hospital

    Shinjuku, 160 0023, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.